Session : Late Breaking Abstracts

LB-8 - Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

Saturday, October 24, 2020

11:00am – 11:10am EDT

Background: SARS-CoV-2 (COVID-19) has disrupted healthcare service delivery globally. CAB+RPV LA is a novel, long-acting antiretroviral therapy (ART) currently in development and is administered intramuscularly monthly or every 2 months by a healthcare provider. COVID-19 and the resultant restrictions on access to some clinical trial sites presents challenges to the continuous delivery (‘implementation fidelity’) of CAB+RPV LA during a pandemic.

Methods: Descriptive analyses were conducted using aggregated data from ongoing CAB+RPV LA clinical trials (LATTE-2, ATLAS, ATLAS-2M, FLAIR, POLAR, and CUSTOMIZE) to evaluate impact of COVID-19 on LA dosing. Data through 15 July 2020 were aggregated, categorized, and summarized to show trends. Data collection is continuously ongoing.

Results: As of 15 July 2020, 1831 participants are currently on CAB+RPV LA across these clinical studies. As of 15 July, 113 (6%) participants had injection visits that were impacted by COVID-19. LA dosing was interrupted in 51 (45%) participants due to clinic closure or staffing constraints, 9 (8%) for self-quarantine, 11 (10%) for confirmed or suspected COVID-19, and 42 (37%) for other reasons. Among participants impacted, 64 (58%) were from N. America, 29 (26%) Europe, 14 (13%) S. Africa, and 3 (3%) Latin America. Majority of participants were male (87, 79%), white (74, 65%), with median age 35 years. Mitigation strategies included short-term oral therapy with CAB+RPV (78, 69%), short-term standard of care ART (28, 25%), and rescheduling of LA injections (6, 5%). Although some are still receiving oral therapy, current median duration of oral therapy has been 45 days. To date, 65 (58%) have restarted LA and viral load data collection is ongoing. No suspected or confirmed virologic failure was observed for any participant impacted by COVID-19 to date.

Conclusion: In the midst of the global pandemic, no treatment interruptions were seen across the ongoing CAB+RPV LA clinical studies. Missed visits were manageable and successfully mitigated, primarily by temporary transition to oral therapy with no resultant virologic failure or emerging resistance through 15 July 2020. CAB+RPV LA is a new HIV-1 treatment modality that has demonstrated implementation fidelity across clinical studies during the current COVID-19 pandemic.

Presenter and Author(s)

Maggie Czarnogorski, MD, MPH

Head, Innovation and Implementation Science
VIIV HEALTHCARE
RTP, NC

Disclosure: ViiV Healthcare (Employee)

Slides

Co-Author(s)

RD

Ronald D'Amico, DO, MSc

Medical Director
ViiV Healthcare
Research Triangle Park, NC

Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)
PB

Paul Benn, MB ChB FRCP

Discovery Medicine Leader
ViiV Healthcare
London, England, United Kingdom

Disclosure: ViiV Healthcare (Employee, Shareholder)
CM

Cynthia C. McCoig, MD

Director, R&D
ViiV Healthcare
Tres Cantos (Madrid), Madrid, Spain

Disclosure: ViiV Healthcare (Employee)
SG

Sandy Griffith, PharmD

Director Clinical Development
ViiV Healthcare
Research Triangle Park, NC

Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)
KH

Krischan J. Hudson, PhD, MPH

Director of Clinical Development
ViiV Healthcare
Research Triangle Park, NC

Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)
KS

Kenneth Sutton, MA

Clinical Development Manager
ViiV Healthcare
Research Triangle Park, North Carolina

Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)
CH

Conn M. Harrington, BA

Clinical Investigation Lead
ViiV Healthcare
Research Triangle Park, NC

Disclosure: ViiV Healthcare (Employee)
SW

Sterling Wu, PhD

Statistics Leader
GlaxoSmithKline
Collegeville, Pennsylvania

Disclosure: GlaxoSmithKline (Employee, Shareholder)
WW

Will Williams, n/a

Study Delivery Lead
GlaxoSmithKline
Collegeville, Pennsylvania

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
KH

Kai S. Hove, MRes

Clinical Study Manager
GlaxoSmithKline
London, England, United Kingdom

Disclosure: GSK (Independent Contractor)
CM

Carlos Martin Espanol, n/a

Pharmacy degree, MSc Drug development
Pharmacy degree, MSc Drug development
London, England, United Kingdom

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
EF

E Jane Fricker, BSc. (Hons) Applied Biochemistry

Senior Clinical Development Director
GlaxoSmithKline
Richmond upon Thames, Surrey, England, United Kingdom

Disclosure: GSK (Employee, Shareholder)
PP

Parul Patel, PharmD

Director, Clinical Pharmacology
ViiV Healthcare
Research Triangle Park, NC

Disclosure: ViiV Healthcare (Employee)
DM

David Margolis, MD, MPH

Director of HIV Drug Development
ViiV Healthcare
Research Triangle Park, North Carolina

Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)